Table 2.

Factors associated with TIL density in ovarian cancer.

T-cell inflamed	Intermediate T-cell inflamed	Non–T-cell inflamed
•IFN response (IRF-1, CXCL-9, -10, −11) •Chemokine receptors (CXCR3) •Ag processing/presentation (β2 microglobulin, TAP transporters, MHC-I and II, CD74) •TCR signalling (CD3D) •Inflammation (IL-15, IL-32, IL-6R, VAV1, complement) •Cytotoxicity (Granzyme B and TNFSF10) •CT Ags (ZNF165, CEP55, ATAD2, MAGEA3, CTAGE5, TTK, PBK, PRAME, CXorf48) •BRCA1-disruption	•High hypoxia •Myofibroblasts •Vascular endothelial cells •Pericytes •Extracellular matrix genes •Angiogenesis genes (VEGF)	•WNT/β-catenin signalling •Cell cycle genes, •Extracellular matrix genes •Low expression of immune cell genes (MHC-I and II), mucins (MUC-1, -16), kallikreins •Low E-cadherin •CXCR6 •Angiogenesis genes (VEGF, ETBR, ET-1)

IRF-1, IFN regulatory factor 1; VEGF, vascular endothelial growth factor; BRCA, breast and ovarian cancer susceptibility protein; MAGE-A3, melanoma-associated antigen 3; IFN, interferon; MHC, major histocompatibility complex; ETBR, endothelin-B receptor.